1. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. (5th July 2022) Authors: Mease, Philip J; Asahina, Akihiko; Gladman, Dafna D; Tanaka, Yoshiya; Tillett, William; Ink, Barbara; Assudani, Deepak; de la Loge, Christine; Coarse, Jason; Eells, Jason; Gossec, Laure Journal: Rheumatology Issue: Volume 62:Number 2(2023) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study. (23rd April 2022) Authors: Tillett, William; McInnes, Iain B; McGonagle, Dennis; Jadon, Deepak R; Ink, Barbara; Assudani, Deepak; Coarse, Jason; Eells, Jason; Coates, Laura C Journal: Rheumatology Issue: Volume 61(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗